Long term immunogenicity of two doses of the quadrivalent HPV vaccine and the effect of an additional dose given five years post-primary vaccination
Two doses of 4vHPV administered at ages 9-11 confers stable antibody levels up to 10 years post-vaccination that can be enhanced with an additional dose given several years later, suggesting the presence of immune memory.
Authors
- Marie‐Hélène Mayrand (ORCID: https://orcid.org/0000-0002-1073-6199)
- Moussa Ouakki (ORCID: https://orcid.org/0000-0002-6265-4734)
- Elizabeth R. Unger (ORCID: https://orcid.org/0000-0002-2925-5635)
- Vladimir Gîlca (ORCID: https://orcid.org/0000-0003-0307-1579)
- Gitika Panicker
- Iulia Gabriela Ionescu
- Chantal Sauvageau (ORCID: https://orcid.org/0000-0002-4300-1658)
Institutions
- Centers for Disease Control and Prevention (US)
- Centre hospitalier universitaire de Québec (CA)
- Institut National de Santé Publique du Québec (CA)
- National Center for Emerging and Zoonotic Infectious Diseases (US)
- Centre Hospitalier de l’Université de Montréal (CA)
Publication Details
- Journal
- Vaccine
- Published
- 2025-10-30
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127893
- Citations
- 1
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.35